Optimising CAR T therapy for the treatment of solid tumors DOI Creative Commons

Norhan Mobark,

Caroline Hull,

John Maher

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Oct. 28, 2024

Introduction Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered T cells has proven transformative in the management of B cell and plasma cel derived malignancies. However, solid tumors have largely to be resistant this therapeutic modality. Challenges include paucity safe target antigens, heterogeneity expression within tumor, difficulty delivery CAR site disease, poor penetration tumor deposits inability circumvent array immunosuppressive biophysical barriers imposed by microenvironment.

Language: Английский

Impacts of ageing on the efficacy of CAR-T cell therapy DOI
Shuhu Qi, Jiaqian Li, Xinyu Gu

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102715 - 102715

Published: March 1, 2025

Language: Английский

Citations

0
Optimising CAR T therapy for the treatment of solid tumors DOI Creative Commons

Norhan Mobark,

Caroline Hull,

John Maher

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Oct. 28, 2024

Introduction Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered T cells has proven transformative in the management of B cell and plasma cel derived malignancies. However, solid tumors have largely to be resistant this therapeutic modality. Challenges include paucity safe target antigens, heterogeneity expression within tumor, difficulty delivery CAR site disease, poor penetration tumor deposits inability circumvent array immunosuppressive biophysical barriers imposed by microenvironment.

Language: Английский

Citations

0